The concept of innovative drugs is hot, and many companies have recently received collective research from institutions.

The concept of innovative drugs has been hot recently, with Shu Taishen and Sansei Guojian both being innovative drug concept stocks among the top ten bull stocks in May. According to People's Financial News statistics, several innovative drug concept stocks have recently been collectively researched by institutions. Health yuan has been researched by 44 institutions from April 25 to May 28. Regarding innovative drugs, Health Yuan stated that the company has successfully built a respiratory innovative drug matrix covering 11 pipelines, with 6 projects advancing to phase II clinical trials or later stages. In addition, a type of innovative flu drug, Mapazi Savewei, is expected to be produced in August 2024, and the company is currently working hard to market the product. Development work on the dry mixed suspension of this drug is also progressing smoothly and will soon enter the clinical stage. Yifang Biology was also researched by more than 20 institutions from May 26 to May 30. Yifang Biology is an innovative drug development company. Currently, the company's product pipeline includes two licensed products on the market, one product in the registration clinical trial stage, two products in phase II clinical trial stage, and multiple pre-clinical research projects. Haichuang Pharmaceutical was researched by more than 20 institutions from May 15 to May 30. The company stated that the new drug application for Duethen Zaluamide Soft Capsules was accepted by the National Medical Products Administration Drug Evaluation Center in November 2023, and it has now been approved for marketing. Duethen Zaluamide Soft Capsules is a type of new drug developed by the company for the treatment of metastatic castration-resistant prostate cancer. In addition, Shenzhou Cell was researched by over 20 institutions on May 22 and 26.